Neuronetics (STIM) Q2 2025: Greenbrook Drives 23% Sequential Clinic Revenue Jump, Margin Mix in Focus

2025-08-05 | By EarningsIQ Research

Greenbrook’s integration propelled Neuronetics to record clinic revenue and operational momentum in Q2, validating the vertical strategy but compressing gross margin as lower-margin services grew as a share of the mix. The business is now prioritizing margin optimization in its Spravato, buy and bill, model, and ramping its Provider Connection Program to drive higher-value referrals. Management’s focus is on achieving cash flow break-even in Q4, with operational efficiencies and payer collections as pivotal levers for the back half of 2025.

Summary

• Greenbrook Integration Outpaces Plan: Vertically integrated clinics are now the main growth engine, driving record revenue but diluting margin.
• Operational Efficiency Initiatives: Cash collections, claim resubmissions, and digital check-in are improving working capital and throughput.
• Margin Mix and Payer Reimbursement: Spravato buy and bill expansion is being recalibrated to protect profitability as payer dynamics prove unpredictable.

Performance Analysis

Neuronetics delivered a step-change in scale this quarter, as the Greenbrook clinic business contributed the majority of revenue and posted a 23% sequential increase in clinic sales. The NeuroStar, TMS system, segment grew at a more modest pace, with 41 systems shipped and treatment session revenue up 13% pro forma. Clinic revenue now accounts for roughly 60% of the business post-acquisition, fundamentally altering the revenue mix and cost structure.

Gross margin compressed sharply to the high 40s percent range, down from prior-year levels, reflecting the heavier weighting of lower-margin clinic services and the early-stage economics of Spravato, buy and bill, reimbursement. Operating expenses rose 25% year-over-year, driven by the inclusion of Greenbrook’s costs and targeted investment in collections and operational support. Cash used in operations improved materially to $3.5 million, reflecting both higher collections and tighter working capital discipline.

• Clinic Revenue Surge: Greenbrook’s 23% sequential growth validates the vertical integration thesis and is now the core growth engine.
• Gross Margin Compression: Revenue mix shift and Spravato buy and bill rollout drove margins down, with further optimization underway.
• Cash Flow Trajectory: Operational improvements and payer collections are narrowing losses, with Q4 targeted for break-even operations.

Despite the margin headwind, Neuronetics is demonstrating improved scale and cash discipline, positioning itself for a sustainable transition to profitability if operational improvements are sustained in the second half.

Executive Commentary

Strategic Positioning

1. Greenbrook Integration as Growth Catalyst

The Greenbrook acquisition has fundamentally shifted Neuronetics’ business model from a pure-play medical device company to a vertically integrated mental health provider. Clinic revenue is now the majority, and operational focus is on maximizing throughput and referral conversion. Standardization of patient intake, digital check-in, and expanded Spravato therapy are driving higher patient volume and improved efficiency, with management citing record clinic revenue and continued site-level growth potential.

2. Spravato Buy and Bill: Margin and Scale Trade-Offs

Spravato, buy and bill, expansion is a double-edged sword: it opens new patient access but introduces reimbursement variability and lower gross margins compared to the, administer and observe, model. Management signaled a more analytical rollout, focusing on payers and sites with adequate reimbursement to avoid margin dilution. This pivot reflects a pragmatic approach to payer risk and capital allocation, balancing growth with profitability discipline.

3. Provider Connection Program and BMP Expansion

The Provider Connection Program is now central to Neuronetics’ commercial strategy, shifting marketing spend from broad campaigns to targeted physician education. By focusing on primary care and non-psychiatrist providers, the company is capturing higher-converting referrals. The Better Me Provider (BMP) program, which delivers three times more treatments per site, is being expanded as a key lever for volume and efficiency, with 395 active sites and 113 more in the pipeline.

4. Operational Efficiency and Cash Collections

Operational improvements are delivering tangible results: digital check-in kiosks, process standardization, and a consultant-led review are unlocking cost savings and throughput gains. Revenue cycle management has improved, with faster collections and systematic resolution of legacy claims. These initiatives are critical for achieving the stated goal of cash flow break-even in Q4.

5. Adolescent Market and Clinical Data Leadership

Adolescent treatment is an emerging growth vector, with new patient starts up 25% in the first half and insurance coverage expanding. Recent publication of real-world data strengthens the clinical case for NeuroStar in younger populations, potentially opening new payer and provider channels in a market with few alternatives.

Key Considerations

Neuronetics’ Q2 results underscore both the promise and complexity of its integrated model, with growth levers and margin risks now more tightly intertwined.

Key Considerations:

• Clinic Revenue Dominance: The business is now primarily a services-led model, with device sales a smaller driver of growth and profitability.
• Margin Volatility: Revenue mix and payer reimbursement in Spravato create ongoing gross margin unpredictability, requiring active management and site-level analytics.
• Working Capital Discipline: Accelerated cash collections and AR cleanup are supporting liquidity, but sustainability depends on continued operational rigor.
• Marketing ROI Shift: Physician-targeted education is proving more efficient than broad consumer marketing, with higher patient conversion and lower spend per referral.
• Debt and Liquidity: Recent debt funding provides runway, but future capital needs will hinge on achieving cash flow break-even and optimizing clinic economics.

Risks

Gross margin remains exposed to revenue mix shifts, especially as clinic and Spravato buy and bill volumes rise. Payer reimbursement unpredictability could pressure profitability if not carefully managed. Integration risk persists as operational synergies and cost savings are not yet fully realized, and any delays in collections or claim denials could impact liquidity. Competition in TMS and behavioral health remains intense, and execution on BMP expansion and adolescent market penetration will be critical to sustaining growth.

Forward Outlook

For Q3 2025, Neuronetics guided to:

• Net revenue of $37 million to $39 million

For full-year 2025, management maintained guidance of:

• Total revenue of $149 million to $155 million
• Gross margin of 48% to 50% (down from prior 55%)
• Operating expenses of $100 million to $105 million
• Year-end cash of $25 million to $28 million (including new debt funding)

Management highlighted several factors that will shape the back half:

• Seasonal Q3 softness due to summer holidays, with Q4 expected to rebound strongly
• Gross margin improvement as Spravato buy and bill is optimized and fixed costs are leveraged

Takeaways

Neuronetics is now a vertically integrated mental health services platform, with Greenbrook clinics driving scale and operational leverage, but also introducing margin and reimbursement complexity.

• Growth Engine Shift: Clinic and services revenue is now the primary driver, with device sales taking a supporting role; this shift brings both scale and new cost pressures.
• Margin Management Critical: Payer dynamics and revenue mix will dictate profitability; management’s willingness to slow Spravato buy and bill expansion to protect margin is a key discipline signal.
• Execution Watch: Sustained progress on collections, operational efficiency, and BMP expansion will determine if the business can deliver on its cash flow break-even target in Q4.

Conclusion

Neuronetics’ Q2 performance affirms the strategic value of the Greenbrook integration, but also surfaces the operational and margin trade-offs inherent in a services-led model. The next two quarters will test management’s ability to optimize payer mix, sustain clinic growth, and deliver on cash flow commitments.

Industry Read-Through

The rapid shift toward vertically integrated care delivery in behavioral health is accelerating, with Neuronetics’ Greenbrook acquisition providing a template for device companies seeking downstream capture. Margin compression from payer-driven service mix is a cautionary signal for others considering similar moves. Spravato reimbursement volatility reveals the challenges of scaling new psychiatric therapies in fragmented payer environments, underscoring the need for robust revenue cycle management. The success of physician-targeted referral programs over traditional marketing may influence go-to-market strategies across medtech and mental health sectors.

STIM Healthcare Mental Health Vertical Integration Clinic Revenue Spravato Gross Margin Adolescent Therapy